Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus irinotecan liposomal II, oxaliplatin, and 5-FU/LV for locally advanced pancreatic cancer (conversion therapy)
ChiCTR2500114836Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in pancreatic cancer (PC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Surgical conversion rate. Started Dec 2025; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2500114836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114836.